Across the pharmaceutical sector, regulatory and access issues have reshaped interactions with Key Opinion Leaders (KOLs).
And with KOL interactions affecting everything from clinical development to product launch, the issue of strategically managing these critical exchanges looms large for small and large pharma organizations alike.
While technology advances have given rise to software platforms that tout their ability to help manage this complex task, some companies are taking an additional approach: using dedicated staff to oversee and coordinate the strategic aspect of KOL management.
Software for KOL management isn’t always easy to use and organizations can’t rely on software alone to strategically manage KOL relationships, said a senior director of medical affairs who participated in a recent study by Best Practices, LLC on the issue.
“We’d love it if the software was easy. That’s a huge issue. I am not sure if it’s there yet. I think you need easy software that documents and records what you need, and then you can pull the data out and you can still do data analysis off that software. But you can’t expect the software to tell who to invite to an ad board or who to use for speakers or who to use for research,” said the senior director.
Read the full article published at whybenchmarking.com
